5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety
Citations Over TimeTop 10% of 2020 papers
Abstract
Androgenetic alopecia (AGA) is a multifactorial disease that carries a significant psychological burden with it. Dihydrotestosterone, the main pathogenic androgen in AGA, is produced by conversion of testosterone, which is catalyzed by the 5-alpha reductase (5-AR) isoenzyme family. Finasteride and dutasteride are inhibitors of these enzymes. Finasteride, which is a single receptor 5-alpha reductase inhibitor (5-ARI), acts by blocking dihydrotestosterone (DHT). Dutasteride, a dual receptor DHT blocker, has a higher potency than its predecessor, finasteride. This review corroborates the evidence of superiority of dutasteride over finasteride, and its comparable safety profile concerning fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
Related Papers
- → 5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety(2020)72 cited
- → Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer(2010)47 cited
- → Phytotherapeutic Alternatives to the Use of Finasteride and Dutasteride as 5-Alpha Reductase Inhibitors in the Treatment of Androgenetic Alopecia: A Review(2024)2 cited
- → The use of 5-alpha-reductase inhibitors for the prevention of prostate cancer(2010)1 cited